Novan Appoints Tomoko Maeda-Chubachi, MD, PhD, MBA as Chief Medical Officer
August 24, 2021 09:00 ET
|
Novan, Inc.
– Dr. Maeda-Chubachi, who served as Novan’s Senior Vice President, Medical has played a key role in the design and execution of the Company’s development programs – – Dr. Maeda-Chubachi was...
Novan Announces Last Patient Visit at Week 24 in B-SIMPLE4 Pivotal Phase 3 Trial of SB206 in Patients with Molluscum Contagiosum
July 28, 2021 08:05 ET
|
Novan, Inc.
– Company previously reported positive topline efficacy and favorable safety data at Week 12 from B-SIMPLE4 in June 2021, with primary endpoint achieving statistical significance with p-value less...
Novan Reports Positive Topline Results from Pivotal Phase 3 Trial of SB206 in Patients with Molluscum Contagiosum
June 11, 2021 06:30 ET
|
Novan, Inc.
– B-SIMPLE4 achieves statistical significance for the primary endpoint with p-value less than 0.0001 – – No serious adverse events related to treatment with SB206 – – Novan intends to submit New...
Novan Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 11, 2021 16:05 ET
|
Novan, Inc.
– Topline efficacy results for ongoing Phase 3 study evaluating SB206 as a treatment for molluscum on track for targeted readout before the end of Q2 2021 – – Preclinical program underway evaluating...
Novan Announces Final Week-12 Visit for Last Patient in B-SIMPLE4 Pivotal Phase 3 Study of SB206 for Treatment of Molluscum
May 03, 2021 08:30 ET
|
Novan, Inc.
– Topline data on track for readout before the end of Q2 2021 – – Currently no FDA-approved therapies for the treatment of molluscum – – Potential for NDA filing no later than Q3 2022 – DURHAM,...
Novan to Present Clinical Data at Annual Meeting of the Society for Investigative Dermatology
April 22, 2021 09:00 ET
|
Novan, Inc.
MORRISVILLE, N.C., April 22, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that data from the Company’s previously completed Phase 3 trials of SB206...
Novan Completes Enrollment in B-SIMPLE4 Pivotal Phase 3 Study of SB206 for Treatment of Molluscum
February 01, 2021 08:05 ET
|
Novan, Inc.
– Topline data on track for targeted readout before the end of Q2 2021 – – SB206, if approved, has the potential to meet an important need for the treatment of molluscum, an area with no current...
Novan Exceeds 60% Enrollment in B-SIMPLE4 Pivotal Phase 3 Study of SB206 for Treatment of Molluscum
December 15, 2020 09:00 ET
|
Novan, Inc.
– Completion of patient enrollment targeted for Q1 2021 with readout of topline results targeted for Q2 2021 – – SB206, if approved, has the potential to meet an important need for the treatment of...
Novan Announces First Patient Enrolled and Dosed in B-SIMPLE4 Pivotal Phase 3 Study of SB206 for Treatment of Molluscum
September 03, 2020 09:05 ET
|
Novan, Inc.
- Topline results targeted for Q2 2021, less than a year away - - SB206, if approved, has the potential to meet an important need for the treatment of molluscum, an area with no current FDA-approved...
Novan Initiates B-SIMPLE4 Pivotal Phase 3 Study of SB206 for Treatment of Molluscum
August 31, 2020 08:05 ET
|
Novan, Inc.
- Clinical sites actively enrolling patients - - SB206, if approved, has the potential to meet an important need for the treatment of molluscum, an area with no current FDA-approved treatment - ...